Low-dose oral etidronate therapy for immobilization hypercalcaemia associated with Guillain-Barré syndrome.
Acta Paediatr
; 90(10): 1202-4, 2001 Oct.
Article
em En
| MEDLINE
| ID: mdl-11697437
UNLABELLED: A low dose of oral etidronate (3.7 mg kg(-1) d(-1)) was administered for immobilization hypercalcaemia associated with Guillain-Barré syndrome in a 12-y-old boy. There was a slight increase in osteoblastic bone formation reflected by alkaline phosphatase and in particular bone-specific alkaline phosphatase during the treatment and serum calcium decreased to the normal range within 2 wk. No adverse side effects were observed and the patient's linear growth subsequently progressed. CONCLUSION: A low dose of oral etidronate is safe and effective for treatment of immobilization hypercalcaemia in children, without inhibiting bone formation.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ácido Etidrônico
/
Hipocinesia
/
Síndrome de Guillain-Barré
/
Hipercalcemia
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Child
/
Humans
/
Male
Idioma:
En
Revista:
Acta Paediatr
Ano de publicação:
2001
Tipo de documento:
Article
País de afiliação:
Japão
País de publicação:
Noruega